Moderna’s new coronavirus infection (COVID-19) vaccine in the US has up to three times the risk of myocarditis compared to Pfizer’s US vaccine, an analysis has found. The incidence of myocarditis after the second dose was evaluated, and this phenomenon was found to be more pronounced in men under 40 years of age.
In order to reduce the side effects, there is advice that the vaccine should be given strategically by identifying the characteristics of each vaccine and taking into account its age etc.
Navid Yanjua, director of data analysis services at the Centers for Disease Control and Prevention, British Columbia, Canada, and a team of researchers between January 1, 2021 and September 9, the same year in British Columbia, approximately 2.2 million people received the Pfizer vaccine and about 87 received the vaccine Moderna The results of the analysis of 10,000 people were published on the 8th in the international academic journal ‘The Journal of the American Heart Association’.
According to the analysis, a total of 59 cases of myocarditis were identified within 21 days after the second vaccination. Pfizer had 21 and Moderna 31. There were a total of 41 cases of ‘pericarditis’, which is inflammation of the pericardium around the heart, 21 cases from Pfizer and 20 cases from Moderna. The combined incidence of myocarditis and pericarditis in Moderna was 35.6 cases per million people, and Pfizer was 12.6 cases.
The research team explained, “This is a relatively higher number than the number of cases of myocarditis in the general population in 2018.
The incidence of myocarditis or pericarditis was higher when the Moderna vaccine was vaccinated, with no difference between men and women. However, the risk of myocarditis or pericarditis was higher in men younger than 40 when they received the Moderna vaccine. In particular, the incidence rate per million people was found to be highest among men aged 18 to 29.
“The risk of developing myocarditis from a vaccine is very low,” says Yanjua.
